ATI Stock Recent News

Allegheny Technologies (ATI) concluded the recent trading session at $59.06, signifying a -1.2% move from its prior day's close.

Allegheny Technologies (ATI) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

CHICAGO, IL, July 05, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP and Levi & Korsinsky, LLP announce that the United States District Court for the Northern District of Illinois Eastern Division has approved the following announcement of a proposed class action settlement that would benefit purchasers of Fortress Value Acquisition Corp. II ("FVAC") or ATI Physical Therapy, Inc. common stock and certain holders of FVAC common stock (NYSE: FAII and NYSE: ATIP):

DALLAS , July 2, 2024 /PRNewswire/ -- ATI (NYSE: ATI) has scheduled the live webcast for its second quarter 2024 earnings conference call on Tuesday, August 6, 2024, at 7:30 a.m. CT (8:30 a.m.

Robert S. Wetherbee becomes Executive Chairman DALLAS , July 1, 2024 /PRNewswire/ -- Kimberly A. Fields today became President and CEO of ATI Inc. [NYSE: ATI].

Here is how Allegheny Technologies (ATI) and Kronos Worldwide (KRO) have performed compared to their sector so far this year.

LIKMEZ™ (ATI-1501) for Metronidazole Oral Suspension 500mg/5mL launched and commercial sales ongoing Funding commitments from U.S. Air Force Academy intended to advance ATI-1701 toward an IND submission to the FDA Engaging regulatory authorities to align on ATI-1801 development plans  HALIFAX, Nova Scotia, June 25, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX:APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced its financial and operational results for the fiscal year ended March 31, 2024 (“FYE 2024”), and provided an update on the Company's strategy for fiscal 2025. All figures are stated in Canadian dollars unless otherwise stated.

The AA&S segment remains weak but showing improvement, and the HPMC segment continues to show strength. Strong demand primarily in the A&D end market should continue to drive growth in the quarters ahead. Expected revenue growth, strong pricing and operational improvement should benefit margin.

BOLINGBROOK, Ill.--(BUSINESS WIRE)--ATI Physical Therapy, Inc. (NYSE: ATIP), a nationally recognized outpatient physical therapy provider in the United States, today provided a settlement notice, which is attached to this press release and has been posted to the investor relations section of ATI's website at Derivative Settlement. About ATI Physical Therapy At ATI Physical Therapy, we are committed to making every life an active life. We provide convenient access to high-quality care to prevent.

Commercial aerospace has seen more than its share of bad press, with the latest being a report of faulty titanium components making it into Airbus and Boeing planes. Given how ATI sources its titanium, I see little direct risk to the company, but can't rule out that this leads to further interruptions in 2024 production schedules. Despite ongoing production challenges in the aerospace sector, ATI has a long runway ahead for revenue growth and margin improvement as widebody production accelerates in 2025 and 2026.